TP53 and cancer: Targeting specific points within apoptotic pathways may bypass classical blocks in apoptosis that are exploited by cancer cells, for instance mutant p53 or enhanced expression of pro-survival Bcl-2 proteins, which can drive cancer development and progression, and facilitate chemoresistance [154].